Boston Scientific Co. (NYSE:BSX) SVP John Bradley Sorenson sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $42.79, for a total value of $256,740.00. Following the completion of the transaction, the senior vice president now directly owns 42,385 shares in the company, valued at $1,813,654.15. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

John Bradley Sorenson also recently made the following trade(s):

  • On Monday, July 15th, John Bradley Sorenson sold 3,728 shares of Boston Scientific stock. The stock was sold at an average price of $42.30, for a total value of $157,694.40.

Shares of BSX traded up $0.37 during mid-day trading on Thursday, hitting $41.80. 58,876 shares of the stock were exchanged, compared to its average volume of 5,758,131. The stock has a market cap of $57.65 billion, a P/E ratio of 28.44, a PEG ratio of 2.54 and a beta of 0.80. Boston Scientific Co. has a 52-week low of $31.56 and a 52-week high of $43.66. The stock has a 50-day simple moving average of $42.52. The company has a current ratio of 1.31, a quick ratio of 1.04 and a debt-to-equity ratio of 0.81.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.01. The business had revenue of $2.63 billion for the quarter, compared to analysts’ expectations of $2.64 billion. Boston Scientific had a return on equity of 23.29% and a net margin of 13.85%. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.41 EPS. On average, analysts predict that Boston Scientific Co. will post 1.56 EPS for the current fiscal year.

BSX has been the topic of a number of research analyst reports. Stifel Nicolaus boosted their price target on Boston Scientific from $44.00 to $46.00 and gave the stock an “in-line” rating in a report on Thursday, June 27th. Piper Jaffray Companies set a $50.00 price target on Boston Scientific and gave the stock a “buy” rating in a report on Wednesday, July 24th. Needham & Company LLC set a $46.00 price target on Boston Scientific and gave the stock a “buy” rating in a report on Wednesday, July 24th. Canaccord Genuity boosted their price target on Boston Scientific from $43.00 to $46.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Finally, Jefferies Financial Group boosted their price target on Boston Scientific from $44.00 to $48.00 and gave the stock a “positive” rating in a report on Thursday, June 27th. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $44.91.

Several institutional investors and hedge funds have recently modified their holdings of BSX. Dimensional Fund Advisors LP grew its position in Boston Scientific by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,978,445 shares of the medical equipment provider’s stock valued at $105,251,000 after buying an additional 51,606 shares during the period. Geode Capital Management LLC grew its position in Boston Scientific by 11.3% during the fourth quarter. Geode Capital Management LLC now owns 16,982,002 shares of the medical equipment provider’s stock valued at $599,030,000 after buying an additional 1,724,046 shares during the period. Mercer Global Advisors Inc. ADV bought a new position in Boston Scientific during the first quarter valued at about $397,000. Ropes Wealth Advisors LLC grew its position in Boston Scientific by 153.7% during the first quarter. Ropes Wealth Advisors LLC now owns 1,522 shares of the medical equipment provider’s stock valued at $58,000 after buying an additional 922 shares during the period. Finally, Flagship Harbor Advisors LLC grew its position in Boston Scientific by 15.7% during the first quarter. Flagship Harbor Advisors LLC now owns 20,898 shares of the medical equipment provider’s stock valued at $802,000 after buying an additional 2,830 shares during the period. 90.60% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Recommended Story: Percentage Gainers

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.